The incidence of non-hematologic AEs, such as fever, thyroid dysfunction, pneumonia, fatigue, increased ALT/AST, gastroenteritis, and rash showed no significant difference between Sintilimab group and Pembrolizumab group. This evidence concerns the gene GPT and gastroenteritis.